Market Place
Sourcing Support
Belief BioMed Collaborates with AskBio on New Gene Therapies
25 Sep 2024 //
PR NEWSWIRE
FDA grants fast track designation to AskBio’s AB-1005 for PD
12 Jul 2024 //
PHARMACEUTICAL-TECHNOLOGY
AskBio Begins Recruitment for Phase 2 Trial of AB-1005 for Parkinson’s
27 Jun 2024 //
PHARMABIZ
AskBio Names Dr. Mansuo Shannon as Chief Scientific Officer
09 Apr 2024 //
CONTRACTPHARMA
First patient in AskBio Phase II gene therapy trial for congestive heart failure
13 Feb 2024 //
PRESS RELEASE
Bayer’s AskBio initiates PII GenePHIT trial in Congestive Heart Failure (CHF)
11 Jan 2024 //
PRESS RELEASE
Bayer and AskBio reveal early safety data for Parkinson`s gene therapy
04 Jan 2024 //
ENDPTS
AskBio announces first patient randomized in Phase 1 Trial of AB-1005
20 Nov 2023 //
INDIAN PHARMA POST
AskBio Presents Preliminary Data from Phase 1 Trial of Gene Therapy for CHF
13 Nov 2023 //
PRESS RELEASE
AskBio Contribution to Advancing Gene Therapy Highlighted at ESGCT 30th Congress
23 Oct 2023 //
PR NEWSWIRE
AskBio Announces First Patient Dosed in Phase 1 / Phase 2 Trial of AB-1003
03 Aug 2023 //
PR NEWSWIRE
AskBio announces 11 presentations offering insights into R&D of AAV therapies
13 May 2023 //
PHARMABIZ
TAAV launches new corporate brand as a reflection of its transformation
02 May 2023 //
PR NEWSWIRE
AskBio to Present Ph1b Results Investigating AB-1005 for Parkinson`s Disease
29 Mar 2023 //
PR NEWSWIRE
AskBio appoints Gustavo Pesquin as CEO
11 Mar 2023 //
PHARMABIZ
Allorion raises $50M Series B; AskBio gets a new CEO
10 Mar 2023 //
ENDPTS
AskBio Announces Gustavo Pesquin as New CEO
09 Mar 2023 //
PR NEWSWIRE
AskBio Receives EC Orphan Drug Designation through BrainVectis for AB-1003
27 Feb 2023 //
PR NEWSWIRE
AskBio Receives EC Orphan Drug Designation for AB-1003 LGMD Treatment
27 Feb 2023 //
CONTRACT PHARMA
Asklepios partners with ReCode on gene-editing platform
10 Jan 2023 //
PHARMACEUTICAL-TECHNOLOGY
AskBio to Collaborate with ReCode for Single Vector Gene Editing Platform
09 Jan 2023 //
PR NEWSWIRE
Recombinant Adeno-Associated Virus (rAAV) Tech Pioneered by AskBio`s Dr. Jude
20 Dec 2022 //
PR NEWSWIRE
Selecta Biosciences Announces Three Presentations at the Upcoming 29th (ESGCT)
11 Oct 2022 //
GLOBENEWSWIRE
BrainVectis gains approval for Phase I/II Huntington’s gene therapy trial
24 Aug 2022 //
CLINICALTRIALSARENA
BrainVectis receives clearance to conduct PI/II trial for its novel gene therapy
23 Aug 2022 //
PRNEWSWIRE
AskBio Appoints Clinical Ops Executives
12 Aug 2022 //
CONTRACTPHARMA
AskBio Bolsters its Global Leadership Team with Two New Executives
11 Aug 2022 //
PRNEWSWIRE
AskBio to Present 11 Abstracts at Upcoming ASCGT
16 May 2022 //
PRNEWSWIRE
Bayer-backed AskBio touts early gene therapy data
16 May 2022 //
FIERCEBIOTECH
Bayer-owned AskBio will shift focus toward DNA in restructure with Touchlight
10 Feb 2022 //
ENDPTS
AskBio’s Gene Therapy Gets Fast Track
21 Jul 2021 //
CONTRACT PHARMA
AskBio Receives FDA Fast Track Designation for LION-101
28 Jun 2021 //
PR NEWSWIRE
AskBio’s Gene Therapy Program Gets Fast Track Designation
28 Jun 2021 //
CONTRACTPHARMA
Bayer enters clinic with experimental cell, gene therapies for Parkinson`s
08 Jun 2021 //
BUSINESSWIRE
AskBio bails on in-licensed gene therapy program after finding issues with 3rd
29 Apr 2021 //
ENDPTS
With Kathy High on board, AskBio makes next leadership play & selects Bayer`s
12 Mar 2021 //
ENDPTS
Selecta & AskBio Initiate First-in-Human Dose-Escalation Study to ImmTOR™
17 Feb 2021 //
PRNEWSWIRE
Bayer & AskBio expand grand gene therapy ambitions with new Parkinson`s program
28 Jan 2021 //
ENDPTS
Bayer sets up cell and gene platform to foster purchased biotech firms
03 Dec 2020 //
REUTERS
Bayer acquires Asklepios to broaden innovation base in cell and gene therapy
28 Oct 2020 //
PRESS RELEASE
Selecta Biosciences and AskBio Receive FDA Rare Pediatric Diseas
19 Oct 2020 //
PRESSRELEASE
Reducing barriers to mainstream gene therapy
03 Sep 2020 //
BIOPHARMA-REPORTER
AskBio receives funding to tackle gene therapy manufacturing challenges
01 Sep 2020 //
EPM
